BARDA

The Center for the Biomedical Advanced Research and Development Authority (BARDA) provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies such as chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks; pandemic influenza (PI), and emerging infectious diseases (EID). Together with its industry partners, BARDA promotes the advanced development of medical countermeasures to protect Americans and respond to 21st century health security threats.

Ashim Subedee, Ph.D

Ashim Subedee is the Acting Director of the Division of Research, Innovation, and Ventures (DRIVe) and the Director of the DRIVe Catalyst Office at the Biomedical Research & Development Authority (BARDA), within the U.S. Department of Health & Human Services (HHS). Ashim leads a team dedicated to fostering health security innovation ecosystem and development and commercialization of next-generation health security technologies through several novel public private partnerships including BARDA Ventures – venture capital investment partnership, BARDA Accelerator Network – partnerships to provide accelerator services and proof of concept funding, and several R&D funding programs like Antiviral Innovation Prize, Type to Treat, ReadyDetect Next-Gen Diagnostics. Prior to BARDA, Ashim was at the NIH where he supported biomedical entrepreneurship and product development by both academic and small business innovators at the NCI Small Business Development Center, NIH Small Business Education and Entrepreneurial Development (SEED) Office, and the Rapid Acceleration of Diagnostics (RADx) program. Ashim joined the federal government as a Presidential Management Fellow and worked at multiple programs across the NIH and at the FDA Center for Drug Evaluation and Research (CDER). He received his PhD in Biological and Biomedical Sciences with a secondary concentration on Science, Technology, and Society from Harvard University.